medulloblastoma (Cancer)
Information
- Disease name
- medulloblastoma
- Disease ID
- DOID:0050902
- Description
- "An infratentorial cancer that is located_in the lower part of the brain and is a type of primitive neuroectodermal tumor." [url:http\://en.wikipedia.org/wiki/Medulloblastoma, url:http\://www.cancer.gov/dictionary?CdrID=45780, url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306779/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02724579 | Active, not recruiting | Phase 2 | Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma | November 17, 2017 | June 30, 2027 |
| NCT03500991 | Active, not recruiting | Phase 1 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | July 26, 2018 | July 26, 2039 |
| NCT03709680 | Active, not recruiting | Phase 1/Phase 2 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | May 24, 2019 | February 25, 2025 |
| NCT01063114 | Active, not recruiting | N/A | Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma | April 2010 | November 2025 |
| NCT00336024 | Active, not recruiting | Phase 3 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | August 6, 2007 | December 31, 2028 |
| NCT03638167 | Active, not recruiting | Phase 1 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | March 19, 2019 | March 2040 |
| NCT00392327 | Active, not recruiting | Phase 3 | Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET | March 26, 2007 | January 30, 2025 |
| NCT03389802 | Active, not recruiting | Phase 1 | Phase I Study of APX005M in Pediatric CNS Tumors | March 1, 2018 | September 30, 2024 |
| NCT02875314 | Active, not recruiting | Phase 4 | HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors | September 2015 | December 2030 |
| NCT01878617 | Active, not recruiting | Phase 2 | A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | June 23, 2013 | January 2028 |
| NCT01326104 | Active, not recruiting | Phase 2 | Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor | September 7, 2010 | June 30, 2024 |
| NCT05934630 | Active, not recruiting | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | July 12, 2023 | July 12, 2028 | |
| NCT04023669 | Active, not recruiting | Phase 1 | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | August 8, 2019 | October 2024 |
| NCT03581240 | Available | An Intermediate Expanded Use Trial of DFMO | |||
| NCT01445288 | Completed | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | December 5, 2006 | ||
| NCT01505569 | Completed | N/A | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | October 20, 2011 | February 1, 2024 |
| NCT01614132 | Completed | Phase 1/Phase 2 | Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults | January 2009 | October 2018 |
| NCT01619865 | Completed | Phase 1/Phase 2 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors | February 21, 2012 | August 27, 2017 |
| NCT01708174 | Completed | Phase 2 | A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) | May 6, 2013 | October 5, 2016 |
| NCT01802567 | Completed | N/A | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer | March 4, 2013 | January 17, 2024 |
| NCT01975116 | Completed | Phase 1 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | August 2013 | April 2015 |
| NCT02017964 | Completed | Phase 2 | Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma | December 24, 2013 | December 31, 2022 |
| NCT02162732 | Completed | N/A | Molecular-Guided Therapy for Childhood Cancer | July 8, 2014 | January 18, 2024 |
| NCT01351870 | Completed | Phase 3 | Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma | April 2004 | March 2020 |
| NCT00404495 | Completed | Phase 2 | Combination of Irinotecan and Temozolomide in Children With Brain Tumors. | April 2007 | December 2011 |
| NCT00407433 | Completed | Phase 2 | Clinical Studies of Gemcitabine-Oxaliplatin | ||
| NCT00520936 | Completed | Phase 2 | A Study of Pemetrexed in Children With Recurrent Cancer | September 2007 | February 2010 |
| NCT00601003 | Completed | Phase 2 | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | January 14, 2008 | October 28, 2022 |
| NCT00867178 | Completed | Phase 1 | Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System | February 25, 2009 | December 22, 2021 |
| NCT00867568 | Completed | Phase 1 | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | March 2009 | February 2016 |
| NCT00880308 | Completed | Phase 1 | Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | March 2009 | July 2013 |
| NCT00994071 | Completed | Phase 1 | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | September 22, 2009 | March 19, 2013 |
| NCT01125800 | Completed | Phase 1/Phase 2 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | February 2011 | October 2014 |
| NCT01171469 | Completed | Phase 1 | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | September 2010 | June 2012 |
| NCT01208831 | Completed | Phase 1 | An East Asian Study of LDE225 | October 2010 | October 2013 |
| NCT01331135 | Completed | Phase 1 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | April 2011 | August 9, 2017 |
| NCT00001502 | Completed | Phase 1 | A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors | April 1996 | March 2000 |
| NCT02441062 | Completed | Phase 2 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | September 2015 | January 20, 2020 |
| NCT02502708 | Completed | Phase 1 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | October 2015 | February 28, 2020 |
| NCT02644291 | Completed | Phase 1 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | May 2016 | June 9, 2022 |
| NCT02747576 | Completed | Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma | July 13, 2016 | August 31, 2018 | |
| NCT03043391 | Completed | Phase 1 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | November 7, 2017 | March 23, 2022 |
| NCT03257631 | Completed | Phase 2 | A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | September 18, 2017 | September 14, 2023 |
| NCT03273712 | Completed | Phase 2 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | September 29, 2017 | May 27, 2020 |
| NCT03434262 | Completed | Phase 1 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | March 5, 2018 | May 24, 2024 |
| NCT04334863 | Completed | Phase 1 | WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors | May 4, 2020 | February 3, 2023 |
| NCT06396481 | Not yet recruiting | Early Phase 1 | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma | April 30, 2024 | December 30, 2027 |
| NCT06323408 | Not yet recruiting | Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas | June 2024 | March 2026 | |
| NCT03173950 | Recruiting | Phase 2 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | July 13, 2017 | April 21, 2027 |
| NCT05128903 | Recruiting | Phase 2 | Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study | July 5, 2022 | December 31, 2025 |
| NCT05835687 | Recruiting | Phase 1 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | April 27, 2023 | March 2028 |
| NCT06161519 | Recruiting | Phase 1/Phase 2 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | January 31, 2024 | November 14, 2033 |
| NCT03583528 | Recruiting | DOTATOC PET/CT for Imaging NET Patients | July 11, 2018 | December 31, 2028 | |
| NCT00840047 | Recruiting | Phase 2 | Methionine PET/CT Studies In Patients With Cancer | July 20, 2009 | July 27, 2027 |
| NCT04049669 | Recruiting | Phase 2 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | October 2, 2019 | October 2, 2027 |
| NCT04081701 | Recruiting | Phase 4 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. | September 4, 2019 | December 31, 2038 |
| NCT04315064 | Recruiting | Early Phase 1 | Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma | April 21, 2020 | December 30, 2025 |
| NCT04337177 | Recruiting | Phase 1 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | October 25, 2021 | June 2024 |
| NCT04402073 | Recruiting | Phase 2 | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma | November 11, 2022 | March 1, 2030 |
| NCT04541082 | Recruiting | Phase 1 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | October 26, 2020 | February 2025 |
| NCT04661384 | Recruiting | Phase 1 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | March 5, 2021 | November 17, 2025 |
| NCT04696029 | Recruiting | Phase 2 | DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | March 29, 2021 | March 2029 |
| NCT04978727 | Recruiting | Phase 1 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | July 1, 2022 | June 30, 2028 |
| NCT05057702 | Recruiting | N/A | Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma | February 22, 2022 | January 31, 2027 |
| NCT05106296 | Recruiting | Phase 1 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | February 8, 2022 | September 2026 |
| NCT05278208 | Recruiting | Phase 1/Phase 2 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | November 21, 2022 | November 2027 |
| NCT05535166 | Recruiting | Phase 2 | Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | December 20, 2022 | July 2035 |
| NCT05672043 | Recruiting | Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China | January 1, 2023 | December 31, 2032 | |
| NCT03251989 | Suspended | Rare CNS Tumors Outcomes &Risk | August 21, 2017 | February 26, 2025 | |
| NCT05382338 | Suspended | Phase 3 | A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | February 20, 2023 | December 20, 2027 |
| NCT02624388 | Terminated | Phase 2 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | August 2016 | September 2021 |
| NCT02212574 | Terminated | Early Phase 1 | Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma | April 4, 2017 | November 9, 2018 |
| NCT04730349 | Terminated | Phase 1/Phase 2 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer | June 3, 2021 | June 22, 2022 |
| NCT00031590 | Terminated | Phase 2 | Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | April 2001 | May 2011 |
| NCT02332889 | Terminated | Phase 1/Phase 2 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | April 2015 | July 2016 |
| NCT01483820 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | December 2011 | December 2014 |
| NCT05125666 | Unknown status | Phase 2 | Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection | October 1, 2020 | March 1, 2022 |
| NCT05131763 | Unknown status | Phase 1 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | March 1, 2021 | December 1, 2023 |
| NCT01857453 | Unknown status | Phase 2 | Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas | April 10, 2013 | December 2021 |
| NCT00983398 | Unknown status | Phase 1/Phase 2 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | July 9, 2009 | December 31, 2022 |
| NCT03675230 | Unknown status | N/A | Study of Tomotherapy HD in Medulloblastoma | January 12, 2018 | June 30, 2020 |
| NCT00231712 | Unknown status | Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant | March 2005 | February 2009 | |
| NCT03734913 | Unknown status | Phase 1 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | January 25, 2019 | July 31, 2021 |
| NCT00180791 | Unknown status | Phase 2 | High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood | July 2002 | |
| NCT02681705 | Unknown status | Phase 2 | Radiation Therapy and Combination Chemotherapy for Medulloblastoma | January 2010 | December 2016 |
| NCT03990597 | Withdrawn | Phase 1 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord | August 19, 2019 | November 24, 2020 |
| NCT02689336 | Withdrawn | Phase 2 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | August 6, 2016 | May 31, 2020 |
| NCT04521946 | Withdrawn | Phase 1 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | January 14, 2021 | December 20, 2022 |
| NCT04270461 | Withdrawn | Phase 1 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | March 17, 2020 | October 17, 2020 |
| NCT01861990 | Withdrawn | Phase 1 | Valproic Acid in Childhood Progressive Brain Tumors | May 2013 | December 2013 |
| NCT03013387 | Withdrawn | Phase 2 | Dosimetry Guided PRRT With 90Y-DOTATOC | January 2017 | October 2019 |
- Disase is a (Disease Ontology)
- DOID:4706
- Cross Reference ID (Disease Ontology)
- GARD:7005
- Cross Reference ID (Disease Ontology)
- ICDO:9470/3
- Cross Reference ID (Disease Ontology)
- MESH:D008527
- Cross Reference ID (Disease Ontology)
- MESH:D018242
- Cross Reference ID (Disease Ontology)
- MIM:155255
- Cross Reference ID (Disease Ontology)
- NCI:C27294
- Cross Reference ID (Disease Ontology)
- NCI:C3222
- Cross Reference ID (Disease Ontology)
- NCI:C3716
- Cross Reference ID (Disease Ontology)
- ORDO:616
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:189925001
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:443333004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0025149
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206663
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1334410
- Exact Synonym (Disease Ontology)
- brain medulloblastoma
- Exact Synonym (Disease Ontology)
- CNS PNET
- Exact Synonym (Disease Ontology)
- CPNET
- Exact Synonym (Disease Ontology)
- infratentorial primitive neuroectodermal tumor
- Exact Synonym (Disease Ontology)
- localized primitive neuroectodermal tumor
- Exact Synonym (Disease Ontology)
- Medulloblastoma, histologically defined
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002885
- OrphaNumber from OrphaNet (Orphanet)
- 616
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008527